Morgan Stanley maintains Recursion Pharmaceuticals at Equal-Weight, lowers price target to $5.60 from $5.90
Morgan Stanley kept Recursion Pharmaceuticals at Equal-Weight but reduced its price target to $5.60 from $5.90, a 5.1% cut. This implies a 105.9% upside from the Nov 17 close of $2.72.



